Abstract : Interleukin IL -4 exhibits strong antitumor effects and IL-4 gene therapy has been used clinically in the treatment of some types of cancer. In the present study, we evaluated the ef cacy of IL-4-transduced tumor cell vaccines in combination with blockade of programmed cell death 1 PD-1 and investigated the mechanisms underlying the antitumor effects of this therapy. A poorly immunogenic murine colorectal cancer cell line i.e. MC38 was transduced to overexpress IL-4. In a therapeutic model, MC38-IL4 cells and anti-PD-1 antagonistic antibodies Ab were inoculated into parental tumorbearing mice. Immunohistochemical analyses and tumor-speci c lysis were also performed. Additive antitumor effects were observed when mice were treated with IL-4 in combination with an anti-PD-1 Ab. Immunohistochemical analysis of the therapeutic model showed marked in ltration of CD4 and CD8 cells into established MC38 tumors of mice treated with anti-PD-1 Ab. Signi cant tumor-speci c cytolysis was detected when the splenocytes of mice treated with both IL-4 and anti-PD-1 Ab were used as effector cells. These results suggest that blockade of the interaction between PD-1 and programmed death ligand 1 PD-L1 enhances the antitumor immune responses induced by IL-4. Thus, IL-4 gene-transduced tumor cell vaccines in combination with PD-1 blockade may be considered as possible candidates for clinical trials of new cancer vaccines.
Interleukin IL -4, a type 2 response inducer, plays a major role in both B and T cell development in the immune system 7, 8 . In addition, it causes a class switch of B cells, upregulates major histocompatibility complex MHC Class II and adhesion molecules, and prevents T cell apoptosis. With respect to its antitumor effects, IL-4 has been shown to have a direct inhibitory effect on tumor cell growth in vivo and in vitro, as well as antiangiogenic effects 9, 10 . It has been reported that IL-4 activates endothelia in the tumor microenvironment, which results in increased in ltration of immune cells 11 . Other reports suggest that eosinophils and neutrophils are responsible for the antitumor effects of IL-4 12, 13 . A recent study has demonstrated that local IL-4 delivery at the site of vaccination activates local DCs, which play a critical role in the initiation, promotion, and regulation of host immune responses and promote T helper Th 1 cell responses 4 . In that study, IL-4 appeared to support DC maturation and to enhance IL-12p70 secretion from DCs. On the basis of these ndings supporting the therapeutic effects of IL-4 against tumors, it has been used clinically in the treatment of tumors.
Programmed death 1 PD-1 was first described as a member of the B7 family of costimulatory molecules that modulate T cell antigen-speci c receptor signaling and control T cell activation, inactivation, and survival 14 . Recently, PD-1 was identi ed as a marker of exhausted T cells in chronic infectious disease 15, 16 . Of the various mechanisms underlying tumor-induced immunosuppression by which tumors escape immune surveillance, numerous studies have suggested a role for an interaction between PD-1 and programmed death ligand 1 PD-L1 in inhibiting the effector functions of antigen-speci c CD8 T cells 17, 18 .
PD-1 is expressed on tumor-in ltrating CD8 T cells in tumors or on antigen-speci c CD8
T cells in hosts with tumors, and the function of these PD-1 T cells is impaired 19, 20 .
PD-L1 has been shown to be expressed at high levels in several different types of cancer 21 , and there is a strong correlation between high PD-L1 expression in tumors and a poor prognosis 22 . Recent studies have shown that blockade of PD-1-PD-L1 signaling restores functional T cell responses in several cancers, subsequently improving clinical outcome 23, 24 .
In the present study, a preliminary investigation of the effects of combination therapy prior to clinical studies, the antitumor effects of a combination of an IL-4-transfected tumor cell vaccine and PD-1 blockade were evaluated in a poorly immunogenic murine colorectal cancer system. When parental tumor-bearing mice were injected with IL-4-overexpressing tumor cells and an anti-PD-1-blocking antibody Ab , the outgrowth of the established parental tumor was signi cantly suppressed. Furthermore, to explore the mechanisms underlying the antitumor effects of the IL-4 plus anti-PD-1 combination, tumors were stained immunohistologically and we tried to induce tumor-speci c T lymphocytes.
Materials and Methods

Mice
Female 6-week-old C57BL / 6 B6 mice were purchased from Sankyo Lab Service Tokyo, Japan for use in experiments when they were 8-12 weeks of age. Mice were maintained in an animal care facility at Showa University. The present study was approved by the Ethics Committee for Animal Experiments of Showa University permission no.
2011-1111 .
Cell lines, culture medium, and reagents
The MC38 murine colorectal adenocarcinoma cell line B6 mouse origin and yeast arti cial chromosome-1 YAC-1 lymphoma cells were maintained in RPMI 1640 medium supplemented with 10 heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU / mL penicillin, 100 g / mL streptomycin, 10 mM HEPES buffer, 1 mM minimum essential medium MEM sodium pyruvate, and 0.1 mM MEM non-essential amino acids complete medium ; CM in a humidi ed incubator with 5 CO 2 in air at 37 . All cell culture reagents were purchased from Life Technologies Gaithersburg, MD, USA . The YAC-1 cells were used as target cells to assess non-speci c killing in cytolytic assays.
The MC38 cell line was genetically modified to produce murine IL-4 MC38-IL4 , as described previously 25 . Expression of IL-4 was con rmed by ELISA using a commercially 
Therapeutic models
To evaluate the potential to treat established tumors, we measured the size of established wild-type WT tumors in mice treated with genetically modi ed MC38 cells and antibody, as described previously 26 . Briefly, B6 mice were injected with 1 Systems, Minneapolis, MN, USA . DCs were generated from bone marrow cells of B6 mice using murine granulocyte-macrophage colony stimulating factor GM-CSF ; 10 ng / mL and IL-4 10 ng / mL , obtained from Pepro Tech EC London, UK , as reported previously 27 .
Cytolytic assays were performed 7 days after the last stimulation using the responder cells as effector cells.
Cytolytic assays
Tumor-stimulated effector cells were assessed for cytolytic activity against MC38-WT and 
Statistical analyses
The comparative growth of established tumors and T cell responses were assessed using Student s t-tests for two samples with unequal variance. Differences between groups were considered signi cant when P 0.05.
Results
Therapeutic inoculations with IL-4-transduced MC38 tumor cells in combination with anti-
PD-1 Ab suppress the in vivo growth of established MC38 tumors
We Ab to suppress the growth of established tumors somewhat more effectively than MC38-IL4 therapy alone, the difference failed to reach statistical signi cance P 0.289 .
Combined MC38-IL4 plus anti-PD-1 Ab treatment induces CD4 and CD8 cell in ltration into established WT tumors
To analyze the antitumor mechanisms induced by combined MC38-IL4 plus anti-PD-1
Ab therapy, we performed immunohistochemical staining using WT tumor tissues of treated mice. Marked in ltration of both CD4 and CD8 cells was observed following the addition of anti-PD-1 Ab compared with the control group and the group treated with MC38-IL4 alone Table 1 ; Fig. 2 . These results suggest that the antitumor effect of MC38-IL4 plus anti-PD-1 Ab combination therapy is dependent on both CD4 and CD8 cells.
Marked tumor-specific cytolysis is detected when splenocytes from mice treated with both
MC38-IL4 and anti-PD-1 Ab are used as effector cells
Mice were initially inoculated with MC38-IL4 and / or anti-PD-1 Ab on Days 0, 7, and 14. Immunoreactive cells were counted in 5 microscopic fields 400 without-knowledge of the experimental group. Results are reported as mean number of positive cells S.D. Fig. 2 . There was marked infiltration of CD4 and CD8 cells into established wild-type tumors in mice inoculated with MC38-IL4 cells in combination with anti-PD-1 Ab. B6 mice were injected s.c. three times with MC38-IL4 cells and anti-PD-1 Ab, either alone or in combination, in the contralateral ank to that containing the established wild-type tumor. Tumor tissues were harvested 4 days after therapeutic inoculation and were stained with anti-CD4 and anti-CD8 Abs. Immunoreactive cells were observed using light microscopy 400 . 
